Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:UNCY)

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire 6 days ago

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 13, 2024

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

GlobeNewswire November 11, 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire October 28, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

GlobeNewswire October 16, 2024

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire October 14, 2024

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

GlobeNewswire October 9, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

GlobeNewswire September 24, 2024

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

GlobeNewswire September 16, 2024
View More News ››

Opinion & Analysis (NDAQ:UNCY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:UNCY)

Life Sciences Virtual Investor Forum Presentations Now Avail

Just In: $UNCY Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, Sept. 20, 2024 (GLOBE...
whytestocks - September 20, 2024

Unicycive Therapeutics, Inc. (UNCY): Developing Novel Treatm

http://beyondspx.com/2024/08/02/unicycive-therapeutics-inc-uncy-developing-novel-treatments-for-kidney-disease/
MikeTester - August 3, 2024

Unicycive Therapeutics Achieves Study Objective in Oxylantha

Just In: $UNCY Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial@ Successfully...
whytestocks - June 25, 2024

UNCY....flirting with VWAP

Cheers !
Iseneschal - March 10, 2023

UNCY .... thru RBL at $2.63.... on watch still

it better get going.....Me no position
Iseneschal - March 10, 2023

UNCY.....now right in the "thick of res"....$2.50

N>H>O>D.......... All looks good...could go way higher.... I don't know ; ) I just want to say that.... Stops save...
Iseneschal - March 10, 2023
View more Bullboard ››

Majestic Gold Corp.

Majestic Gold Corp.

Majestic Gold Corp. is engaged in mineral resource exploration, development and extraction. It operates the Songjiagou open ...
View More »